Background The association between psoriasis and cardiovascular diseases (CVD) is well documented yet the underlying mechanisms remain unknown. Over-expression of osteopontin (OPN) was reported in plasma of patients with psoriasis; with increased cardiovascular risk factors in these patients. Selenium (Se) compounds are effective in down-regulation of OPN expression.
Objective We investigated the levels of OPN and Se in psoriasis, and their relation to metabolic status in patients to identify a possible link between these markers and co-morbidities observed.
Methods Plasma and tissue samples from 20 patients with psoriasis and 10 control subjects were collected for enzyme-linked immunosorbent assays. The clinical significance of plasma, tissue OPN and plasma Se levels in patients vs. control subjects was analysed in relation to metabolic disorders.
Results Plasma and tissue OPN were significantly higher in patients than in controls (P < 0.001). Plasma Se levels were significantly lower in patients than in controls (P < 0.001). Elevated plasma OPN levels (≥51.10 ng/mL) and depressed plasma Se (≤5.19 μg/dL) were significantly associated with the occurrence of psoriasis. Plasma OPN negatively correlated with plasma Se in patients (P = 0.003), but not in controls (P = 0.183).
Conclusions High plasma OPN and low plasma Se levels are predictable factors for occurrence of psoriasis. Further studies examining the effects of Se supplementations on the levels of plasma OPN, together with their effects on psoriasis outcome and cardiovascular risk factors in these patients, are needed.